Sirolimus-Eluting Balloon in Femoropopliteal Disease

Drug-eluting balloons (DEB) with paclitaxel have shown efficacy and safety in the treatment of femoropopliteal disease. Sirolimus-eluting balloons (DEB S) are currently being introduced.

This new drug acts during the cellular resting phase (G0) and is considered potentially more effective than paclitaxel, which is a cytostatic drug. However, there is no conclusive evidence in this regard yet.

The SELUTION SFA study included 134 patients with femoropopliteal intermittent claudication who received percutaneous transluminal angioplasty (PTA) with a DEB S.

The primary endpoint (PEP) was primary patency, defined as restenosis (peak systolic velocity ≥2.5) and clinically driven target lesion revascularization.

The mean patient age was 74 years, and most subjects were men. Overall, 60% of patients had diabetes, 90% had hypertension, 7% had renal insufficiency, and 22% had suffered a stroke. 

Additionally, 97% of the patients were at Rutherford stage 2 or 3. Mean lesion length was 124 mm and the vessel diameter was 5 mm, with 23% total occlusions and 27% moderate to severe calcification.

Read also: Pacientes con antecedente de cirugía de revascularización miocárdica y un nuevo evento de SCA no ST ¿Estrategia invasiva rutinaria?

Technical success was achieved in all patients, with a procedural success rate of 96%. The residual lesion rate was 20% and 2% of patients required bailout stenting.

At 12 months, the PEP was 87.9%, and the rate for clinically driven target lesion revascularization reached 97%. The non-related mortality rate was 6.5%; there were no amputations, and researchers observed a sustained improvement in functional class and an increase in the ankle-brachial index.

Conclusion

The SELUTION SFA JAPAN study showed that the new SELUTION sirolimus-eluting balloon is safe and effective for the treatment of femoropopliteal disease in symptomatic patients.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: A Novel Sirolimus-Coated Balloon for the Treatment of Femoropopliteal Lesions The SELUTION SFA Japan Trial.

Reference: Osamu Iid, et al. J Am Coll Cardiol Intv 2024 Article in Press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

IVUS-Guided vs. Angiography-Guided Drug-Coated Balloon Angioplasty in the Treatment of Femoropopliteal Lesions

Angiography has traditionally been the primary imaging technique for endovascular therapy guidance in patients with peripheral artery disease. However, as it only provides two-dimensional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...